PHGE.U Stock Overview
A clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
BiomX Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.40 |
| 52 Week High | US$0.82 |
| 52 Week Low | US$0.048 |
| Beta | 1.32 |
| 11 Month Change | -2.47% |
| 3 Month Change | 14.25% |
| 1 Year Change | 21.21% |
| 33 Year Change | -95.09% |
| 5 Year Change | n/a |
| Change since IPO | -96.30% |
Recent News & Updates
Recent updates
Shareholder Returns
| PHGE.U | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.5% | 2.0% | -0.3% |
| 1Y | 21.2% | 12.4% | 22.3% |
Return vs Industry: PHGE.U exceeded the US Biotechs industry which returned 12% over the past year.
Return vs Market: PHGE.U underperformed the US Market which returned 24.2% over the past year.
Price Volatility
| PHGE.U volatility | |
|---|---|
| PHGE.U Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.4% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: PHGE.U's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine PHGE.U's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 65 | Jonathan Solomon | www.biomx.com |
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company’s product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials.
BiomX Inc. Fundamentals Summary
| PHGE.U fundamental statistics | |
|---|---|
| Market cap | US$22.55m |
| Earnings (TTM) | -US$37.13m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs PHGE.U overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHGE.U income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$37.14m |
| Earnings | -US$37.13m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.53 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PHGE.U perform over the long term?
See historical performance and comparison